Medical writing support was provided by Diana Marouco, PhD, and Liam Gillies, PhD, of Apollo, OPEN Health Communications, and funded by Novo Nordisk A/S, in accordance with Good Publication Practice 3 (GPP3) guidelines (www.ismpp.org/gpp3)
The Inconvenience of the Pill: The oral form has strict intake requirements to work effectively
Kidney Impairment Semaglutide is FDA-approved to reduce the risk of Chronic Kidney Disease (CKD) worsening in individuals with Type 2 Diabetes and CKD, and it may be used under medical supervision in this group
Novo Nordisk: Top Legal Representatives Novo Nordisks top legal representative was from Japan-based Sonoda & Kobayashi, followed by Murayama Yasuhiko of Shiga International Patent Office
This is why people experience such dramatic results on their tirzepatide weight loss first month